FdaApplication
NDA 215430
Identifiers
- fda_app_no: NDA215430
Properties
| Property | Value |
|---|---|
| applicant_name | AXSOME THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2022-08-18 |
Revenue by product
AUVELITY
| Period | Revenue |
|---|---|
| Q2 2026 | $180.3M |
| Q1 2026 | $153.2M |
| Q3 2025 | $136.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AUVELITY | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | 105MG;30MG | TABLET, EXTENDED RELEASE;ORAL |
| AUVELITY | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | 105MG;45MG | TABLET, EXTENDED RELEASE;ORAL |
2 products